The global healthcare contract development and manufacturing organization (CDMO) market was valued at USD 312.70 billion in 2025 and is forecast to reach USD 814.75 billion by 2035, according to SNS Insider. The market is expected to grow at a compound annual growth rate of 10.05% from 2026 to 2035, reaching USD 344.13 billion in 2026. Growth is being driven by expanding drug and biotechnology-company pipelines, greater outsourcing to control costs, and demand for specialized production of biologics, cell and gene therapies, antibody-drug conjugates and mRNA products. Sponsors are retaining capital for research while relying on partners with specialized technology and regulatory expertise. CDMOs are also adopting single-use and continuous manufacturing, while artificial intelligence and digital twins are helping reduce scale-up cycles by up to 30%. North America held the largest regional share in 2025 at approximately 42.10%, while Asia-Pacific is forecast to grow fastest at about 11.60% annually. The report identifies regulatory complexity, limited capacity and high remediation costs as key challenges, while highlighting opportunities in personalized vaccines, CRISPR gene-editing products, drug-device combinations and expansion across Asia-Pacific and Latin America.